Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready • 2 patents granted in the last 365 days
LABORATOIRE FRANCAIS DU FRACTIONNEMENT ET DES BIOTECHNOLOGIES has 1 pending office action in the Biotechnology & Pharmaceuticals technology area. This action is being examined by 1 distinct examiner, GAO, ASHLEY HARTMAN. The prosecution is confined to a distinct art unit, suggesting a specialized application within the biotech field. GAO, ASHLEY HARTMAN is the busiest examiner, holding the busiest examiner pending action.
The presence of 1 distinct examiner for the 1 pending action indicates a centralized review process. This focused prosecution in a distinct art unit may allow for a more consistent application of examination standards. The pending office action is the only current matter being prosecuted by the company in this specific technology area.
Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §103 only | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| GAO, ASHLEY HARTMAN | 1 | 56.7% | +38.2% |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17056626 | Composition of Concentrated Human Immunoglobulins | GAO, ASHLEY HARTMAN | 5d |
| Art Unit | Apps |
|---|---|
| 1678 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 17056626 | Composition of Concentrated Human Immunoglobulins | GAO, ASHLEY HARTMAN | 1678 | §103 | Final Rejection | 5d | Pending | Nov 18, 2020 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial